CS414591A3 - Cytokinin synthesis inhibition factor, antagonists thereof and its use - Google Patents

Cytokinin synthesis inhibition factor, antagonists thereof and its use

Info

Publication number
CS414591A3
CS414591A3 CS914145A CS414591A CS414591A3 CS 414591 A3 CS414591 A3 CS 414591A3 CS 914145 A CS914145 A CS 914145A CS 414591 A CS414591 A CS 414591A CS 414591 A3 CS414591 A3 CS 414591A3
Authority
CS
Czechoslovakia
Prior art keywords
antagonists
inhibition factor
synthesis inhibition
cytokinin synthesis
cytokine
Prior art date
Application number
CS914145A
Other languages
Czech (cs)
English (en)
Inventor
Timothy R Mosmann
Keving W Moore
Martha W Bond
Paulo J M Vieira
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CS414591A3 publication Critical patent/CS414591A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CS914145A 1989-06-28 1991-12-30 Cytokinin synthesis inhibition factor, antagonists thereof and its use CS414591A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37266789A 1989-06-28 1989-06-28
US45395189A 1989-12-20 1989-12-20

Publications (1)

Publication Number Publication Date
CS414591A3 true CS414591A3 (en) 1992-12-16

Family

ID=27005854

Family Applications (1)

Application Number Title Priority Date Filing Date
CS914145A CS414591A3 (en) 1989-06-28 1991-12-30 Cytokinin synthesis inhibition factor, antagonists thereof and its use

Country Status (22)

Country Link
EP (2) EP0567450B1 (de)
JP (1) JP2813063B2 (de)
KR (1) KR0183035B1 (de)
CN (3) CN1318589C (de)
AT (1) ATE180833T1 (de)
AU (1) AU635058B2 (de)
CA (1) CA2062763C (de)
CS (1) CS414591A3 (de)
DE (1) DE69033143T2 (de)
DK (1) DK0567450T3 (de)
ES (1) ES2132068T3 (de)
FI (1) FI107926B (de)
GR (1) GR3030404T3 (de)
HK (2) HK1040531B (de)
HU (1) HU216310B (de)
IL (1) IL94878A (de)
NO (1) NO301718B1 (de)
NZ (1) NZ234291A (de)
PT (1) PT94514B (de)
SG (1) SG52282A1 (de)
TW (1) TW218383B (de)
WO (1) WO1991000349A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827513A (en) * 1990-06-29 1998-10-27 Schering Corporation Methods of treating insulin-dependent diabetes mellitus by administration of IL-10
ATE116550T1 (de) * 1991-01-16 1995-01-15 Schering Corp Behandlung von neoplastischen krankenheiten mit interleukin-10.
ES2074879T3 (es) * 1991-01-16 1995-09-16 Schering Corp Uso de interleuquina-10 en inmunoterapia adoptiva de cancer.
US6106823A (en) * 1991-01-16 2000-08-22 Schering Corporation Treatment of neoplastic disease with interleukin-10
DE4122402A1 (de) * 1991-07-04 1993-01-07 Schering Ag Verwendung von interleukin 10 zur herstellung von arzneimitteln mit tumorhemmender wirksamkeit
EP0600970B1 (de) * 1991-08-06 1999-12-08 Schering Corporation Verwendung von interleukin-10 analogen oder antagonisten zur behandlung von endotoxin- oder superantigen induzierter toxizität
US5833976A (en) * 1991-08-06 1998-11-10 Schering Corporation Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
ZA931489B (en) * 1992-03-04 1993-10-28 Schering Corp Use of interleuken-10 to suppress graft-vs-host disease
US6277635B1 (en) 1992-03-04 2001-08-21 Schering Corporation Use of interleukin-10 to produce a population of suppressor cells
US6884410B1 (en) 1992-03-04 2005-04-26 Schering Corporation Methods for modulating antigen-specific immune responses
WO1993018783A1 (en) * 1992-03-20 1993-09-30 Schering Corporation Use of interleukin-10 to induce the production of interleukin-1 receptor antagonist
RU2120802C1 (ru) * 1992-08-20 1998-10-27 Шеринг Корпорейшн Фармацевтическая композиция, предназначенная для торможения зависимой от интерлейкина-2 пролиферации опухолевых клеток, увеличения содержания интерферона, лечения воспалительных заболеваний кишечника, потенцирования торможения производства цитокина и ограничения или торможения аллергической реакции замедленного типа
US5601815A (en) * 1992-08-21 1997-02-11 Schering Corp IL-4 and IL-10 to downregulate delayed-type hypersensitivity and cytokine expresion by T-cells
WO1994006473A1 (en) * 1992-09-18 1994-03-31 Schering Corporation Restoration of immunocompetency to t helper cells in hiv infected patients
HU217871B (hu) * 1992-10-01 2000-04-28 Schering Corp. Eljárás hatóanyagként IL-10-et tartalmazó, inzulin-függő diabetes mellitus megelőzésére szolgáló gyógyszerkészítmények előállítására
TW381026B (en) * 1993-01-13 2000-02-01 Schering Corp Method of extracorporally activating cytolytic activity of peripheral blood mononuclear cells and pharmaceutical composition comprising the activated peripheral blood mononuclear cells
WO1994017773A2 (en) * 1993-02-01 1994-08-18 Université Libre de Bruxelles Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
US5328989A (en) * 1993-03-05 1994-07-12 Schering-Plough Purification of human interleukin-10 from a cell culture medium
US5449688A (en) * 1993-03-30 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Method of treating chronic inflammatory diseases
JPH08507930A (ja) * 1993-07-26 1996-08-27 シェリング・コーポレーション ヒトインターロイキン−１０のアゴニストおよびアンタゴニスト
US5650060A (en) * 1994-01-28 1997-07-22 Minnesota Mining And Manufacturing Company Ionically conductive agent, system for cathodic protection of galvanically active metals, and method and apparatus for using same
AU686816B2 (en) 1994-07-05 1998-02-12 Steeno Research Group A/S Immunomodulators
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
CN101307106B (zh) * 1995-12-13 2013-06-12 儿童医学中心公司 内皮细胞增殖抑制剂及其应用方法
AU4385696A (en) * 1996-01-18 1997-08-11 Christian Gronhoj Larsen Synthetic il-10 analogues
EP0901375A1 (de) * 1996-04-17 1999-03-17 Patrick Thomas Prendergast Dhea-kombinationstherapie
AU722570B2 (en) * 1996-09-06 2000-08-03 Schering Corporation Method for lowering cholesterol levels
WO1998047516A1 (en) * 1997-04-17 1998-10-29 Prendergast Patrick T Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors
US6465176B1 (en) * 1998-10-02 2002-10-15 Message Pharmaceuticals, Inc. Method for identifying compounds RNA/RNA binding protein interactions
AU5047600A (en) * 1999-05-27 2000-12-18 Schering Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
WO2001074388A1 (en) 2000-03-31 2001-10-11 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
EP2582386A2 (de) 2010-06-16 2013-04-24 Allergan, Inc. Il-10 und verfahren zur behandlung von augenleiden und anderen erkrankungen
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
CA3054156A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
EP3883635A1 (de) 2018-11-19 2021-09-29 Progenity, Inc. Verfahren und vorrichtungen zur behandlung einer krankheit mit biotherapeutika
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
GB202003428D0 (en) * 2020-03-10 2020-04-22 Univ Dundee IL-10 mutiens

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78197A (en) * 1985-03-22 1991-07-18 Genentech Inc Nucleic acid encoding tgf-beta and its uses
IE62650B1 (en) * 1989-08-04 1995-02-22 David & Sons Ltd Dispensing apparatus
ZA9010188B (en) * 1989-12-20 1991-08-28 Schering Corp Bcrf1 proteins as inhibitors of interferon-gamma

Also Published As

Publication number Publication date
IL94878A0 (en) 1991-04-15
KR920701437A (ko) 1992-08-11
WO1991000349A1 (en) 1991-01-10
NO915115L (no) 1992-02-26
DE69033143T2 (de) 1999-10-21
HUT61048A (en) 1992-11-30
DK0567450T3 (da) 1999-12-13
ATE180833T1 (de) 1999-06-15
IL94878A (en) 2003-01-12
PT94514B (pt) 1998-02-27
KR0183035B1 (ko) 1999-04-01
CN1317569A (zh) 2001-10-17
CA2062763A1 (en) 1990-12-29
FI107926B (fi) 2001-10-31
FI916126A0 (fi) 1991-12-27
JPH04502560A (ja) 1992-05-14
JP2813063B2 (ja) 1998-10-22
ES2132068T3 (es) 1999-08-16
CN1318589C (zh) 2007-05-30
EP0567450B1 (de) 1999-06-02
CN1051393A (zh) 1991-05-15
AU635058B2 (en) 1993-03-11
CA2062763C (en) 2010-01-05
TW218383B (de) 1994-01-01
AU6077090A (en) 1991-01-17
DE69033143D1 (de) 1999-07-08
GR3030404T3 (en) 1999-09-30
CN1317343A (zh) 2001-10-17
HK1040531B (zh) 2008-01-11
NZ234291A (en) 1992-11-25
SG52282A1 (en) 1998-09-28
HU216310B (hu) 1999-06-28
EP0405980A1 (de) 1991-01-02
HK1040531A1 (en) 2002-06-14
EP0567450A1 (de) 1993-11-03
NO915115D0 (no) 1991-12-27
NO301718B1 (no) 1997-12-01
CN1198642C (zh) 2005-04-27
HK1040493B (zh) 2005-12-16
HK1008834A1 (en) 1999-05-21
HU906705D0 (en) 1992-03-30
HK1040493A1 (en) 2002-06-14
PT94514A (pt) 1991-04-18

Similar Documents

Publication Publication Date Title
CS414591A3 (en) Cytokinin synthesis inhibition factor, antagonists thereof and its use
IL119461A (en) 4,7-disubstituted -7H-pyrrolo ¬2, 3-d¾pyrimidines
EP0335901A4 (en) Methods and compositions for the treatment of non-ige-mediated diseases
CA2069428A1 (en) A mammalian cytokine, il-11
DK20690A (da) Alkoxy-1,2,4-triazolo(1,5-c)pyrimidin-2-sulfonamider, fremgangsmaade til deres fremstilling og mellemprodukter
CA2193993A1 (en) New hil-4 mutant proteins used as antagonists or partial agonists of human interleukin 4
IL94602A0 (en) Polypeptides and polypeptide analogues
CA2123315A1 (en) Therapeutic agents which are antagonists or partial agonists of human interleukin 4
RU94044322A (ru) Замещенные в кольце z-амино-1,2,3,4-тетрагидронафталины и 3-аминохроманы
NO922456L (no) Bcrf1-proteiner som inhibitorer av interferon-gamma
EP0361284A3 (de) T-Zellen-Wachstumsfaktor
CA2094275A1 (en) Methods and compositions for the treatment of cell proliferation disorders
ATE111357T1 (de) Synergetische immunostimulierende zusammensetzung und ihre verwendung.
IL106591A0 (en) An interferon alpha/beta binding protein,its preparation and pharmaceutical compositions containing it
IT8721560A0 (it) Procedimento per la purificazione di interferone.
IT8504867A0 (it) Dispositivo di fissaggio per piastre frontali regolabili di parti di mobile estraibili.
ES8802309A1 (es) Procedimiento para la obtencion de piridiletil-dihidropiridinas
CA2080355A1 (en) Isolated Viral Protein Cytokine Antagonists
ITMI931034A1 (it) Processo per la preparazione di proteine inibenti i ribosomi

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic